The Regulatory Mix

Sponsored by Tailwind Pharma, LLC

Welcome to The Regulatory Mix — your go-to briefing for FDA guidances, cGMPs, and the real-world events that shape pharmaceutical quality. This podcast is human-curated but AI-assisted, crafted for regulatory professionals, quality leaders, and curious minds who want to stay ahead in an ever-evolving compliance landscape. Each episode breaks down: 🔍 Key FDA guidances and current Good Manufacturing Practices ⚠️ Recent FDA warning letters and enforcement trends 💡 Practical insights from real-world pharma and compounding cases Whether you’re a seasoned expert or new to the quality game, The Regulatory Mix turns complex regulatory language into actionable takeaways — keeping you sharp, informed, and audit-ready. Follow along and join the conversation — because compliance isn’t just a checkbox. It’s a mindset. #RegulatoryAffairs #FDACompliance #PharmaQuality #cGMP #Podcast #TheRegulatoryMix #Compounding #DrugManufacturing Disclaimer: This podcast is for informational and entertainment purposes only. Interpretations of hosts may differ from official regulations or final agency positions. Always consult a qualified regulatory professional for compliance decisions. Sponsored by Tailwind Pharma, LLC https://www.tailwindconsult.com

  1. Jun 5

    From Minimal to Enhanced: ICH Q8, Q9, and Q10 (R5) and the Modern Quality Playbook

    On this episode of The Regulatory Mix, the hosts break down the newly updated FDA guidance on ICH Q8, Q9, and Q10 Questions and Answers (R5) and what it means for modern pharmaceutical development, manufacturing, and lifecycle management. Published by FDA on May 29, 2026, the guidance revises the earlier R4 Q&A document and clarifies how industry should apply ICH Q8(R2) Pharmaceutical Development, ICH Q9(R1) Quality Risk Management, and ICH Q10 Pharmaceutical Quality System in an integrated way. The episode explores the distinction between the traditional “minimal” development approach and the enhanced Quality by Design approach, emphasizing that both remain acceptable, but the enhanced approach is encouraged because it can create greater process understanding, operational flexibility, and lifecycle robustness. The discussion also highlights one of the most important themes in the guidance: process validation is no longer viewed as a one-time event, but as a lifecycle that includes process design, qualification, and ongoing process verification. The hosts also examine key concepts such as design space, real-time release testing, and control strategy development. The guidance makes clear that companies do not need to adopt design space or RTRT to comply, but those tools may support stronger science, earlier control, and more flexibility when properly justified. At the same time, the expectation for a sound control strategy remains universal regardless of whether a product was developed using a traditional or enhanced approach. The discussion then turns to the broader pharmaceutical quality system implications under ICH Q10, including how quality risk management, knowledge management, and continual improvement should work together across the product lifecycle. The guidance also reinforces that while there is no formal ICH Q10 certification and no requirement for a formal IT-based knowledge management platform, firms are still expected to systematically develop, use, and transfer knowledge to maintain a state of control and support effective decision-making. The takeaway is that ICH Q8, Q9, and Q10 are not standalone concepts. Together, they form the backbone of a modern pharmaceutical quality system built on science, risk, process understanding, and lifecycle discipline. For companies trying to improve flexibility without losing control, this updated Q&A guidance serves as a practical bridge between theory and inspection-ready execution. Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

    15 min

  2. May 17

    Flexible by Design: FDA’s CMC Playbook for Cell and Gene Therapy Products

    On this episode of The Regulatory Mix, the hosts break down the FDA’s flexible Chemistry, Manufacturing, and Controls framework for human cellular and gene therapy products and why that flexibility has become essential for modern product development. Unlike traditional drug programs, cell and gene therapies often involve highly complex manufacturing, limited patient populations, short shelf lives, and product-specific logistical constraints that make conventional development models difficult to apply. The episode explores how the FDA has adapted its expectations to reflect those realities while still maintaining the statutory requirement that products be shown to be safe, pure, and potent. Rather than forcing a one-size-fits-all model, the Agency allows sponsors to use phase-appropriate CGMP approaches during development, apply risk-based comparability assessments, and leverage prior platform knowledge or experience from similar products where scientifically justified. The discussion also highlights how these flexibilities affect core CMC functions, including release criteria, process validation, analytical validation, and commercial specifications. For many cell and gene therapy products, the FDA recognizes that limited lot numbers and patient-specific manufacturing may make traditional validation expectations impractical. In response, the Agency permits more tailored approaches, including scientifically justified batch numbers for process performance qualification, concurrent release of PPQ batches in certain cases, flexible stability strategies, and post-approval refinement of release specifications as more data becomes available. The hosts also examine the broader regulatory implications of this framework. These flexibilities are not a lowering of standards, but a risk-based adjustment designed to accelerate development for serious or life-threatening conditions with unmet medical need. The message is clear: the FDA is willing to be flexible on the path, but not on the destination. Sponsors still need a defensible control strategy, robust scientific rationale, and a clear plan for how process understanding will mature from the clinical stage into commercial licensure. The takeaway is that CMC flexibility in the cell and gene therapy space is now a strategic regulatory tool. Sponsors who understand how to use that flexibility responsibly may be better positioned to move innovative therapies through development without sacrificing quality, control, or long-term licensure viability. Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

    11 min

  3. May 11

    The Inspection Starts Before FDA Arrives: AI Triage, One-Day Audits, and the New Oversight Model

    On this episode of The Regulatory Mix, the hosts break down the FDA’s latest push to modernize oversight through artificial intelligence, risk-based triage, and a new one-day screening inspection pilot. This shift represents more than an efficiency upgrade. It signals a broader move away from episodic, checklist-style audits and toward a more continuous, data-driven model of regulatory surveillance. The episode explores how the FDA is pairing new inspectional approaches with expanded internal AI capabilities. Through platforms like HALO and Elsa 4.0, the Agency is consolidating data from multiple systems and using that information to identify lower-risk facilities for shorter screening inspections while preserving the ability to escalate quickly when concerns arise. The result is a new regulatory reality in which the inspection process effectively begins before an investigator arrives on site. The discussion also highlights what this means for regulated industry. A one-day inspection is not a lighter inspection. It is a faster test of whether a firm’s quality systems, compliance signals, and data footprint are coherent enough to withstand scrutiny immediately. Prior inspection history, complaint trends, recalls, adverse event data, and inconsistencies in registered operations can all shape the narrative that investigators bring with them into the facility. The hosts also examine the broader enforcement message behind this modernization effort. While the FDA is rapidly integrating AI into its own workflows, it has also made clear that industry remains fully responsible for the compliant use of AI in regulated operations. This creates a dual expectation: firms must understand how the Agency is using AI to prioritize oversight, while also ensuring that their own internal AI tools are governed, reviewable, and supported by strong human oversight. The takeaway is clear. FDA oversight is becoming more predictive, more integrated, and more dependent on the quality of the data trail companies create every day. In this environment, inspection readiness is no longer a short-term exercise. It is an ongoing operational discipline built on data integrity, quality culture, and the ability to defend your compliance posture before the first question is even asked. Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

    20 min

  4. May 3

    Inside the PAI and PLI Playbook: How FDA Really Assesses Drug and Biologic Manufacturing Readiness

    On this episode of The Regulatory Mix, the hosts break down FDA Compliance Programs 7346.832 and 7346.832M and what they reveal about how the Agency currently approaches preapproval and prelicense inspections for human drugs and biological products. At the center of the discussion is a clear message: these inspections are not just about checking a facility on inspection day, but about determining whether a site is truly ready to manufacture commercial product as described in the application and in compliance with CGMP expectations. The episode explores the FDA’s shift toward a more holistic, risk-based inspection model, including the growing use of alternative tools such as remote assessments, records requests, and reliance on trusted foreign inspection partners. Rather than treating every application the same, FDA is increasingly weighing product complexity, facility history, process risk, and quality signals when deciding whether an on-site inspection is necessary. That makes inspection readiness less about a single event and more about the maturity and credibility of the overall quality system. The hosts also examine the two major inspection objectives that drive these programs. The first is whether the facility can consistently manufacture the product in accordance with the application and CGMP requirements, spanning quality oversight, facilities, materials, process controls, laboratory systems, and packaging operations. The second is the data integrity audit, where FDA tests whether the records supporting the application are accurate, complete, and trustworthy. When the underlying data lacks factual or contextual integrity, the risk is no longer limited to compliance—it goes directly to whether the application itself can be relied upon. The discussion highlights how these inspections increasingly reflect broader ICH principles, including quality systems, lifecycle management, and quality risk management. It also emphasizes the consequence of serious gaps: FDA’s decision is often binary at this stage—approve or withhold. Significant CGMP failures, weak investigations, poor control of changes, or compromised data integrity can stop an application regardless of how strong other elements may appear on paper. The takeaway is that preapproval and prelicense inspections are not simply technical reviews. They are a full-scale operational credibility test. For companies pursuing approval, success depends on more than compiling data—it depends on proving that the organization, systems, and people can reliably deliver the product exactly as promised. https://www.fda.gov/media/191983/download?attachment Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

    20 min

  5. Apr 25

    First-Cycle or Fall Behind: Strategic Leadership in ANDA Execution

    On this episode of The Regulatory Mix, the hosts break down why ANDA success is not just a regulatory milestone, but a leadership test. Winning in the generic drug space requires far more than filing a technically complete application. It demands enterprise-level coordination across bioequivalence, quality, labeling, intellectual property, manufacturing, facilities, and regulatory affairs, all moving in sync toward one commercial objective: approval with launch readiness on day one. The discussion centers on a simple but often overlooked reality: an ANDA is only as strong as its weakest link. A formulation issue, a mislabeled certification, a delayed DMF amendment, or a facility that is not inspection-ready can each stop the entire application. The hosts explain why the most costly failures are usually not scientific surprises, but predictable breakdowns in cross-functional handoffs, poor dependency management, and weak program ownership. This episode also explores the financial stakes behind ANDA strategy. First-cycle approval and 180-day exclusivity are not merely regulatory achievements—they are enterprise value drivers that can determine market share, pricing power, and portfolio return. Leadership teams that understand Orange Book timing, Paragraph IV risk, tentative approval strategy, and labeling carve-outs are better positioned to protect value and avoid avoidable delays that quietly erode commercial opportunity. The hosts also highlight the importance of FDA engagement under the GDUFA framework, emphasizing that disciplined, credible interactions with the Agency are a performance advantage. Strong responses to information requests, clean management of unsolicited amendments, and accurate facility and Form 356h information all shape not only the fate of a single ANDA, but the credibility of the broader portfolio. The takeaway is clear: ANDAs should be managed as integrated business assets, not isolated regulatory projects. In this environment, strong governance compounds value, while weak alignment destroys it quietly through delays, lost exclusivity, and missed launch opportunities. Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

    18 min

  6. Apr 15

    The Automation Trap: AI in Pharma, Regulatory Risk, and the Fight to Preserve Critical Thinking

    On this episode of The Regulatory Mix, we examine the collision between AI, pharmaceutical manufacturing, and regulatory accountability. As AI moves into Current Good Manufacturing Practice (CGMP) environments, the central question is whether firms can use it without weakening quality oversight and compliance discipline. The Cost of Over-Reliance A recent FDA Warning Letter issued to Purolea Cosmetics Lab serves as a case study for the dangers of unsupervised AI. The firm used AI to generate drug product specifications, procedures, and production records without adequate human review. This led to critical failures: -The firm was unaware of process validation requirements because its AI agent failed to mention them. -The Quality Unit (QU) failed to oversee CGMP compliance or review batch records. -Basic sanitary conditions were neglected, leading to facility contamination. FDA AI Credibility Framework FDA draft guidance introduces a risk-based credibility assessment framework. Model risk is determined by: * Model Influence: The weight of the AI data relative to other evidence. * Decision Consequence: The severity of a wrong decision. * Context of Use (COU): High-risk scenarios, like automated patient monitoring, require the most rigorous validation. The Erosion of Critical Thinking Research on 319 knowledge workers reveals that generative AI is shifting human effort from problem-solving toward verification and stewardship. Key findings include: * Confidence Paradox: High confidence in AI often leads to less critical thinking. * Stewardship Shift: Cognitive work is moving from material production to overseeing AI outputs. * Skill Atrophy: Automation may deprive users of the practice needed to handle complex exceptions. The Bottom Line In regulated industries, AI is an assistive tool, not a substitute for human expertise. Accountability cannot be automated; firms remain responsible for ensuring the safety and quality of every product. REFERENCE LINKS Purolea Cosmetics Lab Warning Letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purolea-cosmetics-lab-722591-04022026 FDA Draft Guidance (January 2025): https://www.fda.gov/media/184830/download Research: AI and Critical Thinking (CHI 25): https://www.microsoft.com/en-us/research/wp-content/uploads/2025/01/lee_2025_ai_critical_thinking_survey.pdf Disclaimer: The views expressed in this episode are personal opinions for educational purposes and do not constitute legal, regulatory, or medical advice.

    21 min

  7. Apr 12

    Track, Trace, Trust: DSCSA and the Final Push to Secure America’s Drug Supply

    On this episode of The Regulatory Mix, the hosts break down the Drug Supply Chain Security Act and the long build toward a fully interoperable system for tracing prescription drugs across the U.S. supply chain. What began in 2013 as a framework to protect patients from counterfeit, stolen, contaminated, and otherwise dangerous drugs has evolved into one of the most operationally significant compliance mandates affecting manufacturers, wholesale distributors, dispensers, repackagers, and 3PLs. At the center of the discussion is the four-part structure of DSCSA: authorized trading partners, product serialization, transaction tracing, and the verification and handling of suspect or illegitimate product. The episode explains how these pillars work together to create accountability across each handoff in the supply chain, and why the shift from lot-level tracing to package-level electronic tracing represents such a major leap in practice. The hosts also examine the “enhanced drug distribution security” phase, including the move to secure electronic exchange of transaction data and the need for systems that can rapidly trace product back through the distribution chain during recalls, investigations, or counterfeit events. The FDA’s stabilization period helped industry transition, but the larger message remains clear: the era of fragmented tracing is ending, and trading partners are expected to operate in a far more connected and transparent system. This episode also highlights how DSCSA is no longer just a statutory requirement sitting in the background. Recent enforcement and counterfeit-drug events show exactly why authorized sourcing, serialization, and product verification matter. As implementation matures, DSCSA is becoming a real-world test of whether firms can combine compliance, technology, and operational discipline to protect both product integrity and patient safety. Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

    11 min

  8. Apr 2

    Beyond Biosimilarity: The Push for Interchangeability

    On this episode of The Regulatory Mix, the hosts break down the FDA’s regulatory framework for biosimilar and interchangeable biological products under the Biologics Price Competition and Innovation Act. The episode explains how the 351(k) pathway allows sponsors to rely in part on the FDA’s prior finding for a reference product, while still requiring a strong demonstration of biosimilarity through analytical, nonclinical, and clinical evidence. It also highlights the higher evidentiary bar for interchangeability, including the ability to support pharmacy-level substitution subject to state law. The discussion also covers the business and operational side of development, including BsUFA and PDUFA review timelines, the role of the Purple Book, reference product exclusivity, and how FDA’s review program is designed to improve transparency and increase first-cycle approvals. The episode walks through practical considerations for sponsors, including pediatric requirements, use of non-U.S. comparators, and the scientific bridge needed to support global development strategies. Finally, the episode turns to post-approval lifecycle management, explaining how manufacturing changes for licensed biologics are handled through PAS, CBE, and annual report categories, and why comparability exercises remain central to demonstrating that quality, purity, and potency are maintained after change. This is a useful listen for anyone working in biosimilar development, regulatory affairs, CMC, or quality oversight. Disclaimer: The views discussed are for educational and informational purposes only and do not constitute legal, regulatory, or professional advice. Any opinions expressed are personal and do not reflect the views of any current or former employer, agency, or client.

    16 min
See All (96)

5
out of 5
7 Ratings

About

Welcome to The Regulatory Mix — your go-to briefing for FDA guidances, cGMPs, and the real-world events that shape pharmaceutical quality. This podcast is human-curated but AI-assisted, crafted for regulatory professionals, quality leaders, and curious minds who want to stay ahead in an ever-evolving compliance landscape. Each episode breaks down: 🔍 Key FDA guidances and current Good Manufacturing Practices ⚠️ Recent FDA warning letters and enforcement trends 💡 Practical insights from real-world pharma and compounding cases Whether you’re a seasoned expert or new to the quality game, The Regulatory Mix turns complex regulatory language into actionable takeaways — keeping you sharp, informed, and audit-ready. Follow along and join the conversation — because compliance isn’t just a checkbox. It’s a mindset. #RegulatoryAffairs #FDACompliance #PharmaQuality #cGMP #Podcast #TheRegulatoryMix #Compounding #DrugManufacturing Disclaimer: This podcast is for informational and entertainment purposes only. Interpretations of hosts may differ from official regulations or final agency positions. Always consult a qualified regulatory professional for compliance decisions. Sponsored by Tailwind Pharma, LLC https://www.tailwindconsult.com

Information

  • Creator
    Sponsored by Tailwind Pharma, LLC
  • Years Active
    2024 - 2026
  • Episodes
    96
  • Show Website
    The Regulatory Mix

You Might Also Like